IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical Ltd (NASDAQ: ICCM) announced its submission of a regulatory filing to Health Canada for the approval of ProSense®, a minimally invasive cryoablation system targeting the treatment of breast tumors and other cancers. With current approvals in 14 countries, including the U.S. and Europe, IceCure aims to expand its market presence. CEO Eyal Shamir noted significant interest from Canadian healthcare providers for its technology, particularly as demand for outpatient solutions has surged post-pandemic. An estimated 28,600 Canadian women will be diagnosed with breast cancer in 2022.
IceCure Medical Ltd (NASDAQ: ICCM) has appointed Gilad Glick, former CEO of Itamar Medical, as a strategic advisor. Glick will enhance the commercialization strategy of IceCure's ProSense® System, targeting global markets, especially the U.S. and EU. ProSense®, known for its minimally invasive cryoablation technology, aims to improve treatments for tumors, including early-stage breast cancer. Glick's expertise is expected to significantly impact IceCure's revenue growth and market penetration.
IceCure Medical (NASDAQ: ICCM) announced that its ProSense cryoablation system was featured at the SIR 2022 Annual Scientific Meeting on June 14, 2022. The event showcased the effectiveness of ProSense for breast cancer treatment, drawing interest from U.S. medical clinics and international distributors. Additionally, IceCure secured a distribution agreement with Shanghai Medtronic for the Chinese market. The promising interim data from the ICE3 study indicates ProSense's potential as a safe, minimally invasive alternative for early-stage breast cancers.
IceCure Medical (NASDAQ: ICCM) announced a distribution agreement with Shanghai Medtronic to supply IceSense3 cryoablation systems in mainland China. The contract requires a minimum purchase of $3.5 million over three years, with first deliveries expected in 2022. This partnership aims to enhance market penetration for cryoablation technology, which is currently underutilized in China. The IceSense3 system has already received approval from China's regulatory body, with additional regulatory submissions planned for disposable probes by the end of 2022.
IceCure Medical (NASDAQ: ICCM) announced that its distributor in Brazil, KTRFIOS, has submitted a regulatory filing to the Brazilian Health Regulatory Agency (ANVISA) for the ProSense system. The application targets multiple cancer treatments including breast and prostate cancer, with KTRFIOS guaranteeing at least $6.6 million in sales within five years of approval. Brazil's rising cancer incidence underscores the demand for innovative treatments. CEO Eyal Shamir highlighted this milestone as pivotal for expanding IceCure's global regulatory landscape, which spans 14 countries including the U.S. and Europe.
IceCure Medical Ltd. (NASDAQ: ICCM) reported Q1 2022 revenues of approximately $0.75 million, a 48% decline from $1.4 million in Q1 2021, primarily due to decreased revenue from distribution agreements and lower sales in Asia amidst COVID restrictions. Gross profit was approximately $0.43 million, with a gross margin of 58%. Operating expenses rose to $4.9 million, resulting in a net loss of $4.4 million ($0.12 per share). Despite these challenges, IceCure saw increased commercial activity and plans to further develop its ProSense® System for breast cancer treatment.
IceCure Medical (NASDAQ: ICCM) is set to release its financial results for Q1 2022 on May 18, 2022, at 7:00 am ET. The announcement will be followed by a conference call at 8:30 am ET, featuring Dr. Richard Fine, discussing the ProSense® System, a cryoablation technology for treating tumors. IceCure specializes in minimally invasive treatments for various cancers, including breast, kidney, and lung cancers. The conference call can be accessed via US and international lines provided in the announcement.
IceCure Medical (NASDAQ: ICCM) announced its participation in the European Conference on Interventional Oncology (ECIO) from April 24-27, 2022, showcasing its ProSense® cryoablation system. The event featured a symposium led by Professor Franco Orsi, highlighting cryoablation's effectiveness for renal and adrenal cancers. Interim results from the ICE3 trial revealed a 98% recurrence-free rate in patients treated for low-risk breast cancer. The company aims to expand ProSense®'s regulatory approvals and establish it as a premier cryoablation option globally.
IceCure Medical Ltd. (NASDAQ: ICCM) reported preliminary unaudited revenue of $4.1 million for 2021, up from $3.9 million in 2020, primarily driven by sales from distribution agreements in Europe and the U.S. ProSense® system. Cash and equivalents surged to $25.6 million from $3.5 million in the prior year, aided by $32 million in equity raises. The company plans to enhance its regulatory and commercial strategies in the U.S., China, and Japan and pursue further FDA approvals for breast cancer treatments.
IceCure Medical Ltd. (NASDAQ: ICCM) shared a letter to shareholders reflecting on its achievements in 2021 and outlining objectives for 2022. The company reported positive interim results from the ICE3 clinical trial and noted progress in gaining regulatory approvals in the U.S., China, and Japan. IceCure also successfully raised $32 million in funding and expanded its global distribution network. Looking ahead, the focus will be on commercialization, regulatory clearances, and the development of next-generation cryoablation systems. The company expressed gratitude to its shareholders for their support.